TNF-α and cancer cachexia: Molecular insights and clinical implications

Life Sciences

Volumn 170, Issue , 2017, Pages 56-63

  Patel, Hetal J ^a   Patel, Bhoomika M ^b  

^a Apex Pharmacy   (United States)

^b NIRMA UNIVERSITY   (India)

Author keywords

Acute phase response; Cancer cachexia; Metabolic abnormalities; Skeletal muscle wasting; Tumor necrosis factor alpha (TNF )

Indexed keywords

GLYCOGEN; INSULIN; INTERLEUKIN 1; LIPID; TUMOR NECROSIS FACTOR; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3; CARBOHYDRATE; INTERLEUKIN 6; PROTEASOME; UBIQUITIN; UCP2 PROTEIN, HUMAN; UCP3 PROTEIN, HUMAN;

ADIPOSE TISSUE; ANOREXIA; CACHEXIA; CARBOHYDRATE METABOLISM; GLUCONEOGENESIS; GLYCOGEN SYNTHESIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; MUSCLE ATROPHY; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SKELETAL MUSCLE; SYSTEMIC INFLAMMATION; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; METABOLISM; NEOPLASM;

ADIPOSE TISSUE; ANIMALS; ANOREXIA; CACHEXIA; CARBOHYDRATES; GLUCONEOGENESIS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; LIPIDS; METABOLISM; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3; WEIGHT LOSS;

EID: 85008601729     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.11.033     Document Type: Review

References (101)

1. [1] Fearon, K., Strasser, F., Anker, S.D., et al. Definition and classification of cancer cachexia: an international consensus. Oncology 12 (2011), 489–495.
2. [2] Donohoe, C.L., Ryan, A.M., Reynolds, J.V., Cancer cachexia: mechanism and clinical implications. Gastroenterol. Res. Pract. 2011 (2011), 1–13.
3. [3] Skipworth, R.J., Stewart, G.D., Dejong, C.H., et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction?. Clin. Nutr. 26 (2007), 667–676.
4. [4] Tessitore, L., Costelli, P., Baccino, F.M., Humoral mediation for cachexia in tumor bearing rats. Br. J. Cancer 67 (1993), 15–23.
5. [5] Argiles, J.M., Moore Carrasco, R., Fuster, G., et al. Cancer cachexia: molecular mechanism. Int. J. Biochem. Cell Biol. 35 (2003), 405–409.
6. [6] Sharma, M., Kambadur, R., Sriram, S., et al. Molecular targets of cancer cachexia: opportunities for pharma nutritional approaches. Pharma. Nutrition 2 (2014), 126–128.
7. [7] Argiles, J.M., Martinez, C.G., Llovera, M., et al. The role of tumor necrosis factor- α in muscle wasting disorders. Basic Appl. Myol. 8 (1998), 371–380.
8. [8] Idriss, H.T., Naismith, J.H., TNF- alpha and the TNF receptor superfamily: structure – unction relationship(s). Microsc. Res. Tech. 50 (2000), 184–195.
9. [9] Argilés, J.M., García-Martínez, C., Llovera, M., et al. The role of cytokines in muscle wasting: its relation with cancer cachexia. Med. Res. Rev. 12 (1992), 637–652.
10. [10] Argiles, J.M., Lopez-Soriano, F.J., Busquets, S., Mechanisms and treatment of cancer cachexia. Nutr. Metab. Cardiovasc. Dis. 23 (2013), S19–S24.
11. [11] Vaughan, V.C., Martin, P., Lewandowski, P.A., Cancer cachexia: impact, mechanisms and emerging treatments. J. Cachex. Sarcopenia Muscle 4 (2013), 95–109.
12. [12] Argiles, J.M., Busquets, S., Felipe, A., et al. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int. J. Biochem. Cell Biol. 37 (2005), 1084–1104.
13. [13] Deans, D.A., Wigmore, S.J., Gilmour, H., et al. Elevated tumor IL-1 beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br. J. Cancer 95 (2006), 1568–1575.
14. [14] Todorov, P., Cariuk, P., McDevitt, T., et al. Characterization of a cancer cachectic factor. Nature 379 (1996), 739–742.
15. [15] Vaisman, N., Hahn, T., Tumor necrosis factor – alpha and anorexia- cause or effect?. Metabolism 40 (1991), 720–723.
16. [16] Stovroff, M.C., Fraker, D.L., Swedenborg, J.A., et al. Cachectin/tumor necrosis factor, a possible mediator of cancer anorexia in the rat. Cancer Res. 48 (1988), 4567–4572.
17. [17] Argiles, J.M., Lopez-Soriano, F.J., Toledo, M., et al. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J. Cachex. Sarcopenia Muscle 2 (2011), 87–93.
18. [18] Benjamin, H.L., Tan, F.K., Cachexia: prevalence and impact in medicine. Curr. Opin. Clin. Nutr. Metab. Care 11 (2008), 400–407.
19. [19] Mulligan, H.D., Mahony, S.M., Ross, J.A., et al. Weight loss in a murine cachexia model is not associated with the cytokines tumor necrosis factor- α or interleukin-6. Cancer Lett. 65 (1992), 239–243.
20. [20] Oliff, A., Defeo-Jones, D., Boyer, M., et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50 (1987), 555–563.
21. [21] Costelli, P., Carbó, N., Tessitore, L., et al. Tumour necrosis factor-α mediates changes in muscle protein turnover in a cachectic rat tumour model. J. Clin. Invest. 92 (1993), 2783–2789.
22. [22] Jurdana, M., Cancer cachexia-anorexia syndrome and skeletal muscle wasting. Radiol. Oncol. 43 (2009), 65–75.
23. [23] Baracos, V.E., Hypercatabolism and hypermetabolism in wasting states. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002), 237–239.
24. [24] Winkler, M.F., Body composition changes in cancer cachexia: are they reversible?. Top. Clin. Nutr. 19 (2004), 85–94.
25. [25] Gould, D.W., Lahart, I., Carmichael, A.R., et al. Cancer cachexia prevention via physical exercise: molecular mechanisms. J. Cachex. Sarcopenia Muscle 4 (2013), 111–124.
26. [26] Li, Y.-P., Schwartz, R.J., Waddell, I.D., et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen mediated NF-κB activation in response to tumor necrosis factor α. FASEB J. 12 (1998), 871–880.
27. [27] Li, Y.-P., Reid, M.B., NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am. J. Phys. Regul. Integr. Comp. Phys., 279, 2000, R1165-R70.
28. [28] Garcia-Martinez, C., Lopez-Soriano, F.J., Argiles, J.M., Acute treatment with tumour necrosis factor- α induces changes in protein metabolism in rat skeletal muscle. Mol. Cell. Biochem. 125 (1993), 11–18.
29. [29] Fong, Y., Moldawer, L.L., Morano, M., et al. Cachectin/TNF or IL-1 α induces cachexia with redistribution of body proteins. Am. J. Phys., 256, 1989, R659-R65.
30. [30] Llovera, M., Garcia-Martinez, C., Lopez-Soriano, J., et al. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett. 130 (1998), 19–27.
31. [31] Garcia-Martinez, C., Agell, N., Llovera, M., et al. Tumour necrosis factor-α increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett. 323 (1993), 211–214.
32. [32] Garcia-Martinez, C., Llovera, M., Agell, N., et al. Ubiquitin gene expession in skeletal muscle is increased during sepsis: involvement of TNF-α but not IL-1. Biochem. Biophys. Res. Commun. 217 (1995), 839–844.
33. [33] Llovera, M., Garcia-Martinez, C., Lopez-Soriano, F.J., et al. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem. Biophys. Res. Commun. 230 (1997), 238–241.
34. [34] Reid, M.B., Li, Y.P., Tumor necrosis factor- α and muscle wasting: a cellular perspective. Respir. Res. 2 (2001), 269–272.
35. [35] Li, Y.-P., Atkins, C.M., Sweatt, J.D., et al. Mitochondria mediate tumor necrosis factor- α/NF-kB signaling in skeletal muscle myotubes. Antioxid. Redox Signal. 1 (1999), 97–104.
36. [36] Li, Y.-P., Schwartz, R.J., Waddell, I.D., et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kB activation in response to tumor necrosis factor- α. FASEB J. 12 (1998), 871–880.
37. [37] Guttridge, D.C., Albenese, C., Reuther, J.Y., et al. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19 (1999), 5785–5799.
38. [38] Sen, C.K., Khanna, S., Resznick, A.Z., et al. Glutathione regulation of tumour necrosis factor a-induced NF-kB activation in skeletal muscle L6 cells. Biochem. Biophys. Res. Commun. 237 (1997), 645–649.
39. [39] Johansson, A.S., Erlanson, M., Lenner, P., et al. Late side-effects are common after treatment of Hodgkin's disease. Muscular atrophy following radiotherapy is a neglected risk. Lakartidningen 95 (1998), 44–47.
40. [40] Li, Y.-P., Reid, M.B., NF-kB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am. J. Phys. Regul. Integr. Comp. Phys., 279, 2000, R1165-R70.
41. [41] Giordano, A., Calvani, M., Petillo, O., et al. Skeletal muscle metabolism in physiology and in cancer disease. J. Cell. Biochem. 90 (2003), 170–186.
42. [42] Glickman, M.H., Ciechanover, A., The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002), 373–428.
43. [43] Solomon, V., Baracos, V., Sarraf, P., et al. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 12602–12607.
44. [44] Bodine, S.C., Latres, E., Baumhueter, S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 (2001), 1704–1708.
45. [45] Lecker, S.H., Jagoe, R.T., Gilbert, A., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18 (2004), 39–51.
46. [46] de Palma, L., Marinelli, M., Pavan, M., et al. Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy. Joint Bone Spine 75 (2007), 53–57.
47. [47] Fischer, D., The gene expression of ubiquitin ligase E3α is upregulated in skeletal muscle during sepsis in rats—potential role of glucocorticoids. Biochem. Biophys. Res. Commun. 267 (2000), 504–508.
48. [48] Bossola, M., Muscaritoli, M., Costelli, P., et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. 237 (2003), 384–389.
49. [49] Khal, J., Wyke, S.M., Russell, S.T., et al. Expression of the ubiquitin–proteasome pathway and muscle loss in experimental cancer cachexia. Br. J. Cancer 93 (2005), 774–780.
50. [50] Khal, J., Hine, A.V., Fearon, K.C.H., et al. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. 37 (2005), 2196–2206.
51. [51] Wyke, S.M., Tisdale, M.J., NF-kappaB mediates proteolysis inducing factor induced protein degradation and expression of the ubiquitin–proteasome system in skeletal muscle. Br. J. Cancer 92 (2005), 711–721.
52. [52] Bossola, M., Muscaritoli, M., Costelli, P., et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am. J. Phys. Regul. Integr. Comp. Phys. 280 (2001), R1518–R1523.
53. [53] Hasselgren, P.O., Fischer, J.E., Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann. Surg. 233 (2001), 9–17.
54. [54] Tisdale, M.J., Biology of cachexia. J. Natl. Cancer Inst. 89 (1997), 1763–1773.
55. [55] Tijerina, A.J., The biochemical basis of metabolism in cancer cachexia. Dimens. Crit. Care Nurs. 23 (2004), 237–243.
56. [56] Alvarez, B., Quinn, L.S., Busquets, S., Quiles, M.T., Lopez-Soriano, F.J., Argiles, J.M., (2002) Tumor necrosis factor-alpha exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochim. Biophys. Acta 1542, 66–72Tisdale MJ. Metabolic abnormalities in Cachexia and Anorexia. Nutrition 16 (2000), 1013–1014.
57. [57] Argiles, J.M., Busquets, S., Felipe, A., Toledo, M., Betancourt, A., Marmonti, E., et al. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int. J. Biochem. Cell Biol. 37 (2005), 1084–1104.
58. [58] Argiles, J.M., Busquets, S., Toledo, M., et al. The role of cytokines in cancer cachexia. Curr. Opin. Support. Palliat. Care 3 (2009), 263–268.
59. [59] Ebadi, M., Mazurak, V.C., Evidence and mechanisms of fat depletion in cancer. Nutrients 6 (2014), 5280–5297.
60. [60] Zuijdgeest-van Leeuwen, S.D., van den Berg, J.W., Wattimena, J.L., et al. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism 49 (2000), 931–936.
61. [61] Ryden, M., Arner, P., Fat loss in cachexia—is there a role for adipocyte lipolysis?. Clin. Nutr. 26 (2007), 1–6.
62. [62] Batista, M.L. Jr., Peres, S.B., McDonald, M.E., et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine 57 (2012), 9–16.
63. [63] Fearon, K., Glass, D.J., Guttridge, D.C., Cancer cachexia: mediators, signaling and metabolic pathways. Cell Metab. 16 (2012), 153–166.
64. [64] Zimmermann, R., Strauss, J.G., Haemmerle, G., et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306 (2004), 1383–1386.
65. [65] Sethi, J.K., Hotamisligil, G.S., The role of TNF alpha in adipocyte metabolism. Semin. Cell Dev. Biol. 10 (1999), 19–29.
66. [66] Price, S.R., Olivecrona, T., Pekala, P.H., Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor: the primary regulatory role of the hormone in 3T3-L1 adipocytes. Arch. Biochem. Biophys. 251 (1986), 738–746.
67. [67] Cornelius, P., Enerback, S., Bjursell, G., et al. Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor. Biochem. J. 249 (1988), 765–769.
68. [68] Fried, S.K., Zechner, R., Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J. Lipid Res. 30 (1989), 1917–1923.
69. [69] Kawakami, M., Murase, T., Ogawa, H., et al. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J. Biochem. 101 (1987), 331–338.
70. [70] Ruan, H., Hacohen, N., Golub, T.R., et al. Tumor necrosis factor- alpha suppresses adipocytes- specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor- kappa B activation by TNF- alpha is obligatory. Diabetes 37 (2002), 1084–1104.
71. [71] Hauner, H., Petruschke, T., Russ, M., et al. Effects of tumour necrosis factor-alpha (TNF-α) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 38 (1995), 764–771.
72. [72] Semb, H., Peterson, J., Tavernier, J., et al. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J. Biol. Chem. 262 (1987), 8390–8394.
73. 14C] lipid load in virgin, lactating and litter-removed rats. Biochem. J. 256 (1988), 1055–1058.
74. [74] Machado, A.P., Costa Rosa, L.F.P.B., Seelaender, M.C.L., Adipose tissue in Walker 256 tumor-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res. 318 (2004), 503–514.
75. [75] Zhang, H.H., Halbleib, M., Ahmad, F., Manganiello, V.C., Greenberg, A.S., Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cyclic AMP. Diabetes 51 (2002), 2929–2935.
76. [76] Tisdale, M.J., Metabolic abnormalities in cachexia and anorexia. Nutrition 16 (2000), 1013–1014.
77. [77] Holroyde, C.P., Gabuzda, T.G., Putnam, R.C., et al. Altered glucose metabolism in metastatic carcinoma. Cancer Res. 35 (1975), 3710–3714.
78. [78] Fredrix, E.W., Soeters, P.B., Wouters, E.F., et al. Effect of different tumor types on resting energy expenditure. Cancer Res. 51 (1991), 6138–6141.
79. [79] Falconer, J.S., Fearon, K.C., Plester, C.E., et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg. 219 (1994), 325–331.
80. [80] Tayek, J.A., A review of cancer cachexin and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. 11 (1992), 445–456.
81. [81] Zentella, A., Manoque, K., Cerami, A., Cachectin/TNF-mediated lactate production in cultured myocytes is linked to activation of a futile substrate cycle. Cytokines 5 (1993), 436–447.
82. [82] Tisdale, M.J., Mechanisms of cancer cachexia. Physiol. Rev. 89 (2009), 381–410.
83. [83] Honors, M.A., Kinzig, K.P., The role of insulin resistance in the development of muscle wasting during cancer cachexia. J. Cachex. Sarcopenia Muscle 3 (2012), 5–11.
84. [84] Lecker, S.H., Solomon, V., Mitch, W.E., et al. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J. Nutr. 129 (1999), 227S–237S.
85. [85] Lecker, S.H., Goldberg, A.L., Mitch, W.E., Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J. Am. Soc. Nephrol. 17 (2006), 1807–1819.
86. [86] Noguchi, Y., Yoshikawa, T., Marat, D., et al. Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor α expression in skeletal muscle. Biochem. Biophys. Res. Commun. 253 (1998), 887–892.
87. [87] Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J. Clin. Invest. 116 (2006), 1793–1801.
88. [88] Ozcan, U., Cao, Q., Yilmaz, E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004), 457–461.
89. [89] Aguirre, V., Uchida, T., Yenush, L., et al. The c-Jun NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J. Biol. Chem. 275 (2000), 9047–9054.
90. [90] Aguirre, V., Werner, E.D., Giraud, J., et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277 (2002), 1531–1537.
91. [91] Steinberg, G.R., Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 6 (2007), 888–894.
92. [92] Stephens, J.M., Lee, J., Pilch, P.F., TNF-α induced insulin resistance in 3T3-L1 adipocyte is accompanied by a loss of insulin receptor substrate-1 and GLUT-4 expression without a loss of insulin receptor mediated signal transduction. J. Biol. Chem. 272 (1997), 971–976.
93. [93] Mc Call, J.L., Tuckey, J.A., Parry, B.R., Serum tumor necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br. J. Surg. 79 (1992), 1361–1363.
94. [94] Fearon, K.C.H., Barber, M.D., Falconer, J.S., et al. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J. Surg. 23 (1999), 584–588.
95. [95] Fearon, K.C., Falconer, J.S., Slater, C., et al. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann. Surg. 227 (1998), 249–254.
96. [96] den Brekel, A.J., S-V, Dentener, M.A., Schols, A.M., et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. 13 (1995), 2600–2605.
97. [97] Scott, H.R., McMillan, D.C., Crilly, A., et al. The relationship between weight loss and interleukin 6 in non-small cell lung cancer. Br. J. Cancer 73 (1996), 1560–1562.
98. [98] Falconer, J.S., Fearon, K.C., Ross, J.A., et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75 (1995), 2077–2082.
99. [99] O'Gorman, P., McMillan, D., McArdle, C., Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr. Cancer 32 (1998), 76–80.
100. [100] Barber, M.D., Ross, J.A., Fearon, K.C.H., Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr. Cancer 35 (1999), 106–110.
101. [101] Moshage, H., Cytokines and the hepatic acute phase response. J. Pathol. 181 (1997), 257–266.